TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment

IntroductionCritically ill patients with acute kidney injury (AKI) present high mortality rates. The magnitude of inflammatory response could determine the prognosis of such patients. Continuous renal replacement therapy (CRRT) may play an important role in removing inflammatory mediators in patients with AKI.AimTo investigate whether the magnitude of inflammatory mediator’s removal is associated with mortality among critically ill patients on CVVHDF, a CRRT modality.MethodsThis study consisted of 64 critically ill patients requiring CVVHDF. Plasma levels of C3a, TNF-α, IL-10, IL-6, IL-1β, sTNFRI and sTNFRII were determined by enzyme-linked immunosorbent assay (ELISA) at the beginning of CVVHDF and after 24 h (outlet). Clearance of cytokines during the first 24 h of CVVHDF was calculated. Clinical and laboratory data were acquired from patient’s records data.ResultsMean age of patients requiring CVVHDF was 63 years, 67.2% were men and 87.3% were Caucasian. Thirty-five (35) patients (54.7%) died. Comparing non-survivors with the group of survivors we observed higher incidence of sepsis (68.6 versus 37.9%, p < 0.05), higher APACHE II score (34.8 ± 7.6 versus 29.2 ± 7.1, p < 0.05) and higher lactate levels (23.2 ± 17.6 versus 16.4 ± 6.6, p < 0.05). According to the inter-tertile range of TNF-α clearance (ITR1 (<0.54); ITR2 (0.54–2.93); ITR3 (>2.93)) we found that those patients with higher TNF-α removal by RRT (ITR3) had a better survival. Multivariable analysis showed that lower clearance of TNF-α remained independently associated with high mortality after adjustment for sex, age, use of vasoactive drugs, APACHE II score sepsis, creatinine and lactate before CVVHDF (HR: 0.179, 95% IC: 0.049–0.661, p < 0.01).ConclusionThe attenuation of inflammatory response may be related to the lower mortality observed on those patients with higher TNF-α removal by CVVHDF.     

连续静脉-静脉血液透析滤过治疗多器官功能障碍综合征的临床疗效研究

目的:探讨连续静脉-静脉血液透析滤过(continuous veno-venous hemodialysis filtration,CVVHDF)治疗多器官功能障碍综合征(MODS)的临床疗效。方法:选择我院ICU自2015年1月-2017年2月收治的MODS患者50例作为研究对象,根据随机抽签原则分为观察组与对照组,每组25例。对照组在常规内科治疗基础上给予机械通气治疗,观察组在对照组基础上采用CVVHDF治疗,两组治疗观察时间为30d。观察和比较两组ICU停留时间、呼吸机辅助时间、治疗后APACHEⅡ评分与MODS评分、治疗前后血清IL-6与TNF-α含量的变化及随访6个月的死亡情况。结果:治疗后,观察组ICU停留时间和呼吸机辅助时间均短于对照组(P0.05),APACHEⅡ评分与MODS评分分别为22.33±2.49分和6.42±1.98分,均明显低于对照组(62.19±7.45分和7.29±1.67分)(P0.05)。治疗后,两组的血清IL-6与TNF-α含量都明显低于治疗前,且观察组的血清IL-6与TNF-α含量均明显低于对照组(P0.05)。随访6个月,观察组与对照组的死亡率分别为4.0%和20.0%,观察组的死亡率低于对照组(P0.05)。结论:CVVHDF治疗MODS能有效清除患者炎症因子,缩短ICU停留时间和呼吸机辅助时间,降低患者的死亡率。